Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Latigo Biotherapeutics reported Q3 2026 financial results, ending the period with $401 million in cash to fund operations into 2029. The company also announced the appointment of Todd Smith as President and CEO, replacing Nima Farzan, and updated its Phase 3 onzotrigine trial design to include a Percocet comparator arm.
Term
Q3 2026
“With the proceeds from our IPO, we are well-positioned to continue to execute across our development plans for onzotrigine and LTG-321. For onzotrigine, the addition of a Percocet arm to our Phase 3 bunionectomy trial is intended to provide further support for onzotrigine as an opioid-free pain management option in a second surgical model, while also providing data against a commonly used opioid comparator distinct from the one evaluated in our abdominoplasty program.”
Todd N. Smith, president and chief executive officer
Genesis Energy reported Q3 2026 net income of $2.4 million and Adjusted EBITDA of $130.5 million, with results slightly exceeding internal expectations. The company maintained its quarterly distribution at $0.20 per common unit, representing a 21% increase year-over-year, while reporting a bank leverage ratio of 5.03X.
Term
Q3 2026
“Our third quarter results came in modestly ahead of our internal expectations. Our Offshore Pipeline Transportation segment experienced no disruptions of throughput from weather-related producer shut-ins during what is typically the most active part of hurricane season.”
Grant Sims, CEO of Genesis Energy
“Following the significant financing activity in the first half of the year, there is little to report on the balance sheet this quarter. We ended the quarter with no borrowings outstanding under our $900 million senior secured credit facility, approximately $41.5 million of unrestricted cash on hand, no debt maturities until 2029, and a bank-calculated leverage ratio of approximately 5.03x.”
Orion Energy Systems reported Q2 FY2027 revenue of $21.7M, a 9% increase year-over-year, driven by a 40% surge in LED lighting revenue. Despite the revenue growth, the company reported a net loss of $0.8M and reiterated its full-year revenue guidance of $100M-$102M.
Term
Q2 2027
“Orion enters the second half of FY’27 accelerating our initiatives to achieve diversified growth, sustainable margins and market expansion. Whether it’s rapidly growing engagements with major retail chains and logistics leaders, more and more campuses for hyper-scale data-center operators or expanding incumbencies with global automakers, Orion continues on a trajectory to achieve our profitable growth expectations for the current fiscal year.”
Acacia Research reported Q3 2026 total revenue of $54.4 million, an 8% decrease year-over-year primarily due to lower intellectual property license revenue. The company posted a GAAP net loss of $5.6 million but achieved positive Adjusted EBITDA of $3.9 million and ended the quarter with $346.3 million in cash and liquid assets.
“In the third quarter, Acacia generated total revenue of $54.4 million. Our total revenue excluding our Intellectual Property Operations of $54.2 million increased for the third consecutive quarter and was a near record. We also delivered Operated Segment Adjusted EBITDA of $9.1 million and Total Company Adjusted EBITDA of $3.9 million.”
Martin (“MJ”) D. McNulty, Jr., Chief Executive Officer
“We ended the quarter with approximately $346.3 million, or $3.55 per share, in cash, equity securities and loans receivable, up from $3.43 per share last quarter, with no parent-company debt. With an active acquisition pipeline and a flexible investment mandate, we remain focused on compounding long-term intrinsic value per share through disciplined capital allocation.”
Martin (“MJ”) D. McNulty, Jr., Chief Executive Officer
Iovance Biotherapeutics reported record third quarter 2026 total revenue of approximately $122 million, an 80% increase year-over-year, driven by strong demand for its TIL therapy Amtagvi. The company achieved a record gross margin of approximately 60% and reaffirmed its full-year 2026 revenue guidance of $410 million to $420 million.
Term
Q3 2026
“Third quarter revenue reached a new record of ~$122 million with our highest gross margin ever, driven by continued U.S. Amtagvi demand. We remain on track to achieve our full-year 2026 total revenue guidance of $410 to $420 million and recently marked the tremendous milestone of more than 1,000 commercially treated Amtagvi patients.”
Frederick Vogt, Ph.D., J.D., Interim Chief Executive Officer and President
WW International reported Q3 2026 revenue of $152.9 million, driven by 48% year-over-year growth in Clinical Subscription Revenue. The company achieved a net income of $15.1 million and narrowed its full-year 2026 revenue guidance to a range of $625 million to $630 million.
Term
Q3 2026
“Since joining Weight Watchers on October 1, I made it my priority to listen to our members, coaches, clinicians, registered dietitians, and colleagues. Through these conversations, two core truths emerged: weight loss is personal, and the support people need changes along the way.”
Stephen Bye, President and Chief Executive Officer
“We remained focused on strengthening our two higher-value product offerings and proactively calibrating our spend across our portfolio. That approach helped drive sustained progress in these offerings with four quarters of quarter-over-quarter growth in Core+ subscribers, and the largest year-over-year Clinical Subscription Revenue growth percentage in any quarter of 2026 to date.”
Evergy reported third quarter 2026 GAAP EPS of $2.59 and adjusted EPS of $2.58, driven by warmer weather and regulated investment recovery. The company raised its full-year 2026 adjusted EPS guidance to a range of $4.35 to $4.50 and declared a quarterly dividend of $0.7225 per share.
“We finished the third quarter with strong execution against our operational and financial targets while also advancing our large customer strategy that we expect will continue to drive affordability benefits for our customers. Generation reliability outperformed despite a stern test from significantly warmer weather and record peak demand for both Evergy and the Southwest Power Pool.”
David Campbell, chairman and chief executive officer
“Given results ahead of expectations driven by strong operational performance and warmer weather, we are increasing our 2026 adjusted EPS guidance range to $4.35 to $4.50 per share from $4.14 to $4.34 per share. We increased our dividend by 4%, which supports our long-term payout ratio target range of 50% to 60%.”
David Campbell, chairman and chief executive officer
Apyx Medical reported Q3 2026 total revenue of $14.0 million, up 9% year-over-year, driven by 17% growth in its Surgical Aesthetics segment. The company narrowed its net loss to $1.8 million and achieved positive Adjusted EBITDA of $0.4 million while initiating the full commercial launch of its power liposuction handpiece for the AYON system.
Term
Q3 2026
“We are pleased to report 17% growth in our Surgical Aesthetics business for the quarter, reflecting continued adoption of AYON and the progress we are making in executing our commercial strategy. Over the past year, we have continued to demonstrate the value AYON offers by providing a full suite of complementary body contouring capabilities in one integrated platform. We are building on that foundation with the broader commercial launch of power liposuction, which has received very positive early feedback from surgeons since it received FDA clearance earlier this year. We estimate that approximately 70% of plastic surgeons use power liposuction, making this an important addition that broadens AYON’s appeal.”
Charlie Goodwin, President and Chief Executive Officer
DTE Energy Divestiture to Velocity BidCo LLC for $2.97B
DTE Energy Company entered into a definitive agreement to sell its wholly owned subsidiary, DTE Energy Resources, LLC (d/b/a DTE Vantage), to Velocity BidCo LLC for approximately $2.97 billion. DTE Vantage operates renewable energy projects and custom energy solutions for industrial and commercial customers. The transaction is expected to close no earlier than December 31, 2026, subject to regulatory approvals including HSR and FERC authorization.
N-able reported third quarter 2026 revenue of $137.5 million, representing 4.9% year-over-year growth, and exceeded its Adjusted EBITDA guidance with $43.6 million. The company also highlighted the repurchase of approximately 10.2 million shares during the quarter, representing about 5% of its outstanding stock.
Term
Q3 2026
“As cyberthreats escalate, we believe every business, no matter its size, deserves enterprise-grade protection. That conviction is translating into real-world impact, with our AI-powered, end-to-end cybersecurity platform protecting over 500,000 businesses worldwide. We delivered another quarter of profitable growth and our priorities moving forward are clear: keep innovating, keep sharpening our go-to-market execution, and give more businesses the resilience to withstand whatever comes next.”
John Pagliuca, N-able president and CEO
“The backdrop for cybersecurity remains positive, and we continue to operate with discipline in pursuit of the opportunity ahead. Our repurchase of approximately 5% of our outstanding shares this quarter reflects our confidence in our approach and the long-term value of N-able.”
Teleflex reported Q3 2026 revenue of $567.8 million, representing 3.0% pro forma adjusted constant currency growth. The company raised its full-year 2026 adjusted EPS guidance to a range of $7.50 to $7.75 and completed $350 million in share repurchases since July 1, 2026.
Term
Q3 2026
“We are pleased with our third quarter performance, which included margin expansion and robust earnings per share growth, even when excluding IEEPA tariff refunds.”
Jason Weidman, Teleflex’s President and Chief Executive Officer
“Our priorities are clear: strengthening our foundation by delivering our transformation, inclusive of the completion of our Strategic Divestitures and the Vascular Intervention integration, accelerating our organizational effectiveness, and elevating our growth profile within a balanced capital allocation framework.”
Jason Weidman, Teleflex’s President and Chief Executive Officer
Precision BioSciences announced successful Phase 1 results for PBGENE-HBV in chronic hepatitis B, showing 100% pgRNA loss to undetectable levels at the 0.4 mg/kg dose and evidence of cccDNA elimination. The company also reported that the first patient dosed with PBGENE-DMD for Duchenne muscular dystrophy completed an eight-week safety observation period with no serious adverse events, allowing the Phase 1/2 trial to proceed with additional dosing.
Amylyx Pharmaceuticals reported third quarter 2026 financial results and provided a business update, highlighting positive Phase 3 LUCIDITY trial results for avexitide in post-bariatric hypoglycemia. The company remains on track to submit a New Drug Application (NDA) by the end of 2026 and recently strengthened its balance sheet with approximately $545 million in net proceeds from a public offering.
“The third quarter was a transformational period for Amylyx, as we reported positive topline results from the Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia, bringing us one step closer to potentially delivering a first ever FDA-approved treatment to people living with PBH.”
Keel Infrastructure reported Q3 2026 financial results, highlighting a strategic shift from Bitcoin mining to HPC/AI infrastructure development. The company reported revenue of $28 million and a net loss from continuing operations of $62 million, primarily driven by a $55 million non-cash unrealized loss on capped calls.
“Power supply is getting scarcer while demand keeps climbing. Keel’s 2027 and 2028 power is further advanced, more secure, and closer to delivery than it was last quarter. With competitive tension high at all three near-term sites, and multiple creditworthy parties at the negotiation table, I have every confidence we will sign the right leases for each site, ones that deliver the most attractive returns for our shareholders.”
Ben Gagnon, CEO
“We remain strongly capitalized, with approximately $780 million of cash liquidity and no current need for debt or equity financing before signing a lease. Capital we deploy ahead of a lease becomes part of our equity contribution to a project's financing, and we examine opportunities to recycle capital on an ongoing basis.”
Genprex announced translational analysis results from 11 lung cancer patients treated with its lead gene therapy candidate, Reqorsa (quaratusugene ozeplasmid). The data, presented at the GSA 2026 Annual Scientific Meeting, showed that Reqorsa administration triggers a transcriptional shift toward cellular maintenance, mitochondrial adaptation, and autophagy by 24 hours post-treatment. These findings suggest the TUSC2 gene delivered by Reqorsa enhances cellular resilience to aging-associated stress and deepens the company's understanding of the drug's biological impact.
Shake Shack reported third quarter 2026 financial results with total revenue increasing 15.2% year-over-year to $423.3 million. The company achieved net income of $17.8 million and opened 37 new system-wide locations during the quarter. Same-Shack sales grew 2.5% compared to the prior year period.
1-800-FLOWERS.COM reported fiscal 2027 first quarter revenue of $171.4 million and a net loss from continuing operations of $50.6 million. The company announced a new segment reporting structure (E-Commerce, Wholesale and Other, and BloomNet) and updated its outlook following the sale of PersonalizationMall.com and Things Remembered.
Term
Q1 2027
“During the fiscal first quarter, we began to see signs of progress across our primary websites, with improving net order demand trends and a moderation in the pace of year-over-year declines. While we are still in the early stages of our transformation, these developments are encouraging and suggest that our initiatives are beginning to take hold.”
Adolfo Villagomez, Chief Executive Officer
“Following our announcement last quarter that we were evaluating capital-raising options, we completed the sale of PersonalizationMall.com and Things Remembered during the fiscal second quarter and entered into an agreement to sell our Jacksonville, FL facility. These actions reflect our continued focus on optimizing our capital structure, reducing debt and providing capital to invest in initiatives that improve performance.”
Astec Industries reported Q3 2026 net sales of $352.4 million, a slight increase of 0.7% year-over-year, but posted a net loss of $12.2 million. The company noted that macroeconomic uncertainty and inflationary headwinds impacted margins, leading to a revision of its full-year 2026 Adjusted EBITDA guidance to a lower range of $140 million to $150 million.
Term
Q3 2026
“Third quarter financial results were less than expected as ongoing macroeconomic uncertainty caused a pause in orders earlier in the year by select asphalt plant customers. This, combined with inflationary headwinds, impacted our sales, mix, absorption and margins during the third quarter. Despite this temporary pause and the delayed renewal of the U.S. federal highway bill, underlying demand rebounded in the third quarter as evidenced by our 49.2% growth in backlog.”
Jaco van der Merwe, Chief Executive Officer
“We are revising our full year 2026 Adjusted EBITDA guidance from the previous range of $160 million to $175 million to $140 million to $150 million.”
Frontdoor, Inc. reported third-quarter 2026 revenue of $655 million, a 6% increase year-over-year, and net income of $116 million. The company raised its full-year 2026 outlook and announced a new $1 billion share repurchase authorization following strong cash flow generation.
Term
Q3 2026
“I am proud of how our team produced strong third-quarter results while providing exceptional service for our members during the hottest summer on record. Our team continues to rise to the challenge and find new ways to improve our operations and elevate the member experience. These outcomes reflect the value we provide homeowners, the dedication of our people, and the durability of our business model.”
Bill Cobb, Chairman and Chief Executive Officer
“We delivered higher revenue, Adjusted EBITDA and earnings per share again in the third quarter. Our capital-light business continued to generate strong cash flows and enabled us to accelerate share repurchases in the third-quarter. We now expect to complete our current authorization in November. As a result, our Board of Directors approved a new $1 billion authorization, which reflects our confidence in the business and underscores our commitment to returning excess cash to shareholders.”
Avalo Therapeutics reported its third quarter 2026 financial results, highlighting a cash position of $462.8 million which is expected to fund operations into 2029. The company is advancing its lead candidate, abdakibart, toward a Phase 3 program in hidradenitis suppurativa with initiation planned for the first half of 2027.
“LOTUS provides a strong clinical foundation for advancing abdakibart toward registrational development in hidradenitis suppurativa. The efficacy and safety results observed across both dosing regimens, together with the potential for once-monthly administration, give us confidence in abdakibart’s potential to become an important new treatment option for patients with HS.”
Unity Software reported its third quarter 2026 financial results, achieving its first GAAP profitable quarter since its IPO with net income of $122 million. Total revenue grew 32% year-over-year to $622 million, driven by a 59% increase in strategic revenue and strong performance in the Grow Solutions segment.
Term
Q3 2026
“Third-quarter performance was our strongest ever, with Vector growing 126% year-over-year and 40% quarter-over-quarter, and the first GAAP profitable quarter since our IPO.”
Matt Bromberg, President and CEO of Unity
“We are seeing the compounding impact of our flywheel strategy: more creators make more games on our platform, and more games fuel the need for more discovery through advertising.”
Lexicon Pharmaceuticals reported Q3 2026 financial results and provided clinical updates, including the completion of enrollment for its Phase 3 SONATA-HCM study. The company also confirmed it has achieved the safety data requirements for its ZYNQUISTA NDA resubmission in type 1 diabetes.
Term
3 months
“This quarter brought Lexicon into sharper focus as a cardiometabolic company and has positioned us to approach 2027 with strong momentum and multiple near-term potential catalysts and paths to value creation.”
Mike Exton, Ph.D., Lexicon’s chief executive officer and director
“As we prepare for several important milestones across our portfolio, we remain focused on investing prudently to support execution and position the Company for long-term success.”
Middleby Corp reported record Q3 2026 net sales of $653 million, representing 7.7% organic growth, and raised its full-year organic sales growth guidance to 7-8%. The company also announced a leadership transition where Steve Spittle will succeed Tim FitzGerald as CEO on April 1, 2027, following the successful separation of its Food Processing business.
Term
Q3 2026
“We delivered record third quarter net sales and strong organic growth across our commercial foodservice business. Adjusted EBITDA increased 10% from the prior year, and our performance exceeded the high end of our guidance ranges for net sales, Adjusted EBITDA and Adjusted EPS. These results reflect the benefits of our strategic investments, industry-leading innovation and continued focus on customer-driven solutions.”
Tim FitzGerald, CEO of the Middleby Corporation
“Following the successful separation of our Food Processing business and the launch of Midera as an independent public company, Middleby is now a focused, pure-play commercial foodservice leader. We remain committed to disciplined capital allocation and repurchased 1.0 million shares during the third quarter and 4.8 million shares year to date. Our strong third quarter performance and continued business momentum give us confidence to raise our full year 2026 guidance.”
Global Payments reported third quarter 2026 GAAP revenue of $3.31 billion and adjusted EPS of $3.58, representing a 10% increase. The company reaffirmed its full-year 2026 outlook and increased its run-rate expense synergy target for the Worldpay integration to $650 million.
Term
Q3 2026
“We delivered third quarter results consistent with our expectations, reflecting the ongoing disciplined execution of our team members worldwide. We continue to make substantial progress integrating Worldpay, giving us confidence to increase our run-rate expense synergy target to $650 million.”
Cameron Bready, chief executive officer
“Our third quarter financial performance demonstrates the durability of our business model and our ability to generate sustainable growth, margin expansion and strong free cash flow.”
Rockwell Automation reported fiscal 2026 full-year results with reported sales up 8% to $9.4 billion and Adjusted EPS increasing 27% to $13.42. The company introduced fiscal 2027 guidance projecting organic sales growth of 6% to 9% and Adjusted EPS between $14.50 and $15.50.
Term
FY2026
“Rockwell delivered a strong finish to a great year, with broad-based topline growth, margin expansion, and double-digit earnings growth. Our results underscore the differentiation of our strategy and operating model, as we continue to gain share, strengthen our leadership in core markets, and expand our position in high-growth areas including semiconductor and data centers.”
Shift4 Payments, Inc. reported its financial results for the third quarter ended September 30, 2026. The company provided detailed non-GAAP metrics including gross revenue less network fees, Adjusted EBITDA, and Adjusted Free Cash Flow to evaluate its performance in the 'Experience Economy'.
Monte Rosa Therapeutics reported Q3 2026 financial results, highlighting a cash position of $582.6 million and $87.5 million in milestone payments triggered by Novartis initiating Phase 2 studies for MRT-6160. The company also announced positive Phase 1 data for MRT-8102 in cardiovascular disease and the initiation of multiple Phase 2 clinical trials across its pipeline.
Counterparty
Novartis
Term
3 months
“The last quarter marks a tremendously important step forward for our clinical portfolio, with a positive readout from the GFORCE-1 study of MRT-8102, the initiation of Phase 2 development for MRT-2359, and the advancement of our partnered VAV1 program into two Phase 2 studies.”
Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics
“We are particularly excited about the opportunity in gout, where there is a substantial unmet need for effective flare prevention that is well tolerated with prolonged use.”
Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics
Cartesian Therapeutics reported Q3 2026 financial results, ending the period with $124.7 million in cash to support operations into 2028. The company is advancing its Phase 3 AURORA trial for Descartes-08 in myasthenia gravis with data expected in Q1 2027 and a BLA filing planned for mid-2027.
Term
Q3 2026
“With Phase 3 AURORA data expected in the first quarter of 2027, our focus this quarter remains on execution, both in the clinic and in preparing the organization for a commercial launch. Ahead of our anticipated BLA submission in mid-2027, we have expanded our medical affairs and commercial teams to drive launch readiness.”
Carsten Brunn, Ph.D., President and Chief Executive Officer
BKV Corp reported Q3 2026 net income of $29.4 million and average net production of 981.2 MMcfe/d. The company also announced a cost reimbursement agreement with a leading frontier AI lab to support doubling planned modular power generation at the Temple Energy Complex to 400 MW.
Shutterstock, Inc. filed its Form 10-Q for the period ending September 30, 2026, providing a detailed overview of its quarterly financial performance and operational results. The report includes condensed consolidated financial statements and management's discussion on the company's liquidity and capital resources.